Dicerna Stock Price, News & Analysis

Dicerna Pharmaceuticals was a biotechnology company that specialized in developing RNA interference (RNAi) therapeutics using its proprietary GalXC technology platform to silence disease-causing genes in the liver. The company focused on treatments for rare inherited diseases, cardiovascular conditions, and liver disorders including non-alcoholic steatohepatitis (NASH). Dicerna was acquired by Novo Nordisk in December 2021 for approximately $3.3 billion and now operates as a wholly-owned subsidiary.